FORM PTO-	1449				ATTY. DOCKS 30727.001	NO. IP1		SERIAL NO 09/518,50		
LIST OF	PATEN	ITS AND OTHER IT	MS FOR API	PLICANT'S	APPLICANT:				· · · · · · · · · · · · · · · · · · ·	
	NFORN	MATION DISCLOSU	RE STATEME	ENT	METABASIS 7 FILING DATE:	THER		EUTICS, I	NC.	
₩U	(Use several sheets if necessary) U.S. PATENT DE U.S. PATENT			March 5, 1999	l	1	1827M.			
		0188						'CC/	\	
		FEB 2 5 2007					_	MAR	VE	<u>`</u>
	PARE	3.	U.S. PA	TENT DOCL	JMENTS	"T(HO	MAR O 7	2002	
EXAMINER INITIAL			DATE		NAME	CLAS		CLASS 60	FILI 7/20 DA	ING TE
TUM	AA	3,018,302	01/23/62	Bielefeld, e	t al.	26	0	46	100	
M	AB	5,157,027	10/20/92	Biller, et al.		5/4	,	167		
Ju	AC	5,658,889	8/19/97	Gruber, et	al	51	1	43		
			FOREIGN	PATENT DO	CUMENTS					_
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	co	DUNTRY	CLAS	s	SUB CLASS	TRANSL YES	ATION ON
1/M	AD		30.05.79	EP (and En -Abstract)	glish language			Î	-	_
1/1/				EP (and En	glish language					
100	(AE	0 072 531 A1	23.02.83	-Abstract) EP (U.K. Er	ıglish language	1				
	AF	0 158 057 A	16.10.85	translation)			4			<u> </u>
	AG	0 180 276 A1	28.12.88	EP						
	АН	0 261 283 A1	22.09.86	EP		<u> </u>				,
	Al	0 161 955 A1	21.11.85	EPO						ļ
	AJ	0 338 372 A2	25.10.89	EPO				_		
	AK	0 353 692 A2	07.02.90	EPO	49, 44					<u> </u>
	AL	0 481 214 B1	22.04.92	EPO						
	АМ	492 738	30.06.70	CH (and El Abstract)	nglish language					
V	AN	987,378	17.09.70	UK						
EXAMINER:	211	us OM I	(i	DAT	TE CONSIDERED:	18	0	<i>></i> -		
EXAMINE	R: In	itial if reference is ion if not in conform	considered, v	whether or not of considered.	citation is in conf Include a copy of	orman	ce w	vith MPEP with next	609; E)raw

FCRM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets (f necessary)

30727.001 IP1

SERIAL NO. 09/518,501

APPLICANT:

METABASIS THERAPEUTICS, INC.

FILING DATE: March 5, 1999 **GROUP:** 1614 ♠

			 [E8								7
			PATE	² foreign	PATENT DOCUMENTS				MA,		VEN
EXAMI INIT			DOCUMENT NUMBER	MARY PATE	COUNTRY	CL) SSS	ECEUB ELG	5 //>	YES YES	
	M	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)				-///	YES 1600	29 ₀₀
		AP	96/01267	18.01.96	wo						
		AQ	97/03679	06.02.97	wo						
		AR	98/09668	12.03.98	wo						
		AS	98/39342	11.09.98	wo						
	7	AT	98/39343	11.09.98	wo						
	<u> </u>	AU	98/39344	11.09.98	wo						

	ОТН	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
10	h AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997
	AW	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoprptidase (NEP, EC 3.4.24.11) Inhibitors, J. Med. Chem. 37: 498-511 (1994)
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of <i>cis</i> -2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," <u>J. Chem. Res. Synop.</u> , 5: 122-123 (1989)
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an –2-y]!-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" J. Med. Chem. 38:488-495 (1995)
	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324-325 (1983)

EXAMINER: Examiner	Maries CIM CS	19	DATE CONSIDERED:	glor
	Initial if reference is considered	ed, whether or	not citation is in confor	mance with MPEP 609; Draw
line through ci	itation if not in conformance an	d not conside	red. Include a copy of the	nis form with next
communicatio	n to applicant			

FCRM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT INFORMATION DISCLOSURE STATEMENT 5 2002

(Use several sheets if necessary

ATTY. DOCK-T NO. 30727.001 IP1 09/510, APPLICANT: METABASIS THERAPEUTICS: METABASIS THERAPEUTICS: MAR 0 7 2002 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) 7 100/290 Farguhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 BA (1985)Farguhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983) BB Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem. Pharmac. 38: 3193-3198 (1989) BC Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864 du BD Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984) BE Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987) BF Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," J. Antimicrob. Chemotherap. 14: 93-99 BG (1984)Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986) BH Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'didehydrothymidine (d4T) - A New Pro-Nucleotide Approach," Bioorg. Med. Chem. Lett. 7: 99-104 (1997) BI Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979) BJ Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993) BK

EXAMINER: DATE CONSIDERED: Examiner

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next

FCRM PTO-1449

ATTY, DOCKET NO. 30727.001

SERIAL NO. 09/518,501

APPLICANT:

METABASIS THERAPEUTIOS

(Use several sheets if necessary) FEB 2 5 2002 2

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT

INFORMATION DISCLOSURE STATEMEND

FILING DATE: March 5, 1999 **GROUP:** 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. BL 1979, Pages 53-61. Nifantyev, et al., "Synthesis and Structure of Some Stable Phospholane-Phospholanes." Phos. Sulfur & Silicon 113, 1-13 (1996) BM Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" Journal of Organic Chemistry of the USSR (English Translation 13:1489-1492 (1977)) BN Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" Journal of Organic Chemistry of the USSR (English Translation 17:1156-1165 (1981) BO Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) BP S-294 (1993) Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Sin, 41: 9-16 (1994) BQ Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," J. Med. Chem. 37: 1857-1864 (1994) BR Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999) BS Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982) BT

	7		_	
EXAMINER:		DATE CONSIDERED:	[[]	100

AMINER! Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next

Please type a plus sign (+) inside this box

FEB 2 5 2002 rsons are required to res

Approved for S Patent and Trademark Office: & ond to a collection of information unless?

Complete if Known

PTO/SB/08A (08-00) Sugh 10/31/2002. OMB 0651-0031 DEPARTMENT OF COMMERCE contains a valid OMB control number

Under the Paperwork Reduction Act of 1983 Substitute for form 1449A/PTO

& THADENADA

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

09/518.501 **Application Number** March 3, 2000 Filing Date First Named Inventor Erion 1624 Group Art Unit

(use as many sheets as necessary)

of Sheet

T. McKenzie Examiner Name 030727.0013.CIP1 Attorney Docket Number

TONTON SOON **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Date of Publication of U.S. Patent Document Where Relevant Passages or Relevant Name of Patentee or Applicant Examine Cite Cited Document Kind Code² (If known) of Cited Document MM-DD-YYYY Number Figures Appear Initials*

				FOREIGN PA	ATENT DOCUMEN	TS		-
Т		1	Foreign Patent Doc	ument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind Code' (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Т
								-
								4_
								- -
	-	 						上

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
pr	AA	Coppi, et al., "Lewis Acid Mediated Condensation of Alkenols and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)	
	AB	Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gene Therapy, 5, 1070-1078 (1988).	
	AC	Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phsophonate (\$)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy," Vol. 42, p. 1146-1150 (May 1998).	
V	AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues1," The Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).	

λ/'				
Examiner Cons McCo	Date Considered	a/	12/03	
Cigital Circ			7	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box 3

Sheet

FEB 2 5 2002

TRADEMA

PTO/SB/08A (08-00)
Approved for Set through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2 of 2

Co	mpiete if Known	`\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Application Number	09/518,501	~~~~~
Filing Date	March 5, 1999	M.
First Named Inventor	Erion	1//
Group Art Unit	1624	
Examiner Name	T. McKenzie	7/2 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Attorney Docket Number	030727.0013.CIP1	120
		1500/200
RATURE DOCUMENTS		
e of the article (when appropriate) issue number(s), publisher, city a	, title of the item (book, magazine, jou ind/or country where published.	mai, T²

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
Nu	AE	He, et al., "Inactivation of Cytochrome P450 3A4 by Bergamottin a Component of Grapefruit Juice," Chem. Res. Toxicol, Vol. 11, No. 4, p. 252-259 (1998).	
8	AF	Jounaidi et al., "Retroviral Transfer of Human Cytochrome P450 Genes for Oxazaphosphorine-based Cancer Gene Therapy," Cancer Research, Vol. 58, p. 4391- 4401 (Oct. 1, 1998).	
			 -
			-
	<u></u>		
	· .		_
			l

			1		
Examiner Signature Cun	M	Date Considered	2/13	1/03	
· ·					

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S ATTY. DOC T NO. 30727.0013.CIP1 09/518,501 APPLICANT: METABASIS THERAPEUTICS, INC. FILING DATE: March 5, 1999 March 5, 1999

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE	
My	AA	3,018,302	01.23.62	Bielefeld, et al.				
	AB	5,157,027	10/20 92	Biller, et al.				
	AC	5,658,889	8/19/97	Gruber, et al.				

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT AND DE				SUB		LATION
1NITIAL 1	 -	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
CF VI	AD	0 002 062 A	30.05.79	EP (Abstract)		<u> </u>		
	AE	0 072 531 A	23.02.83	EP (Abstract)				
	AF	0 158 057 A	16.10.85	EP (Abstract)				
	AG	0 180 276	28.12.88	EP				
	AH	0 261 283	22.09.86	EP				
	AI	0 161 955 A	21.11.85	EPO				
	AJ	0 338 372 A	25.10.89	EPO				
	AK	0 353 692 A	07.02.90	EPO				
	AL	0 481 214 A	22.04.92	EPO				
	AM	492 738 A	30.06.70	СН				
<u> </u>	AN	16 93 219 A	17.09.70	DE (Abstract)				

		 1
EXAMINER:	DATE CONSIDERED:	0~
7		

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY.	DOC	ΓNO.	
30727	7.0013	.CIP1	

SERIAL NO. 09/518,501

APPLICANT:

METABASIS THERAPEUTICS, INC.

FILING DATE: March 5, 1999 **GROUP:** 1614

FOREIGN PATENT DOCUMENTS EXAMINER & TRAC TRANSLATION SUB INITIAL **DOCUMENT NUMBER** DATE COUNTRY CLASS CLASS YES DE (and English language AO 35 12 781 A1 10.04.85 U.S. Patent No. 4,952,740) AP 96/01267 A 18.01.96 WO AQ 97/03679 A 06.02.97 WO AR 98/09668 A WO 12.03.98 **AS** 11.09.98 98/39342 WO AT 98/39343 11.09.98 WO ΑU 98/39344 11.09.98 WO

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)					
gr	AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09 241284 A (Yamishata Koji; Nippon Soda Co. Ltd), 16 September 1997				
	AW	DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoprptidase (NEP, EC 3.4.24.11) Inhibitors, <u>J. Med. Chem.</u> 37: 498-511 (1994)				
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of <i>cis</i> -2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," <u>J. Chem. Res. Synop.</u> , 5: 122-123 (1989)				
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]!-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)'" J. Med. Chem. 38:488-495 (1995)				
4	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324 (1983)				

	rr
EXAMINER:	DATE CONSIDERED:
Examiner) Phy Col W , V a	2/9/02
EXAMINER: Initial if reference is considered, whether	her or not citation is in conformance with MPEP 609; Draw
line through citation if not in conformance and not co	neidered. Include a compressible forms with most
the through citation if not in comormance/and not co	isideted. Include a copy of this form with next

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOC	
30727.0013.0	CIP1

SERIAL NO. 09/518,501

APPLICANT:

METABASIS THERAPEUTICS, INC.

FILING DATE: March 5, 1999 **GROUP:** 1614

THER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) TE TRAC Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2oxazaphosphorinan-2-yl)-ß-D-arabinosylladenine and 9-[5'-(2-Oxo-1.3.2dioxazaphosphorinan-2-yl)-ß-D-arabinosylladenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 BA (1985)Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-BB Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983) Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in BC Cultured Cells," Biochem. Pharmac. 38: 3193-3198 (1989) Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski BD Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864a Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters BE Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984) BF Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987) Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," J. Antimicrob. Chemotherap, 14: 93-99 BG (1984)Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation. Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986) BH Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'didehydrothymidine (d4T) - A New Pro-Nucleotide Approach," Biogra, Med. Chem. BI Lett. 7: 99-104 (1977) Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of BJ Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979) Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester BK

	Δ	0	
EXAMINER:	$\int_{\Omega} \int_{\Omega} \int_{\Omega$	DATE CONSIDERED:	
Examiner	10mcs//////	11	4/02
EXAMINER: Ir	nitial if reference is considered, who	ether or not citation is in conforman	ee with MPEP 609; Draw
line through citat	tion if not in conformance and hot	considered. Include a copy of this for	orm with next

Amides," Heterocycles 35: 1185-1203 (1993)

FORM PTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

OVPE VC (Use several sheets if necessary)

ATTY. DOC	
30727.001	3.CIP1

SERIAL NO. 09/518,501

APPLICANT:

METABASIS THERAPEUTICS, INC.

FILING DATE: March 5, 1999 **GROUP:** 1614

ت مل	Nifont'ov et al. "1.3.2 Diazonhadenharinanes". 7h Obeheb Khim, Vol. 40 No. 4					
3	A TRAD	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, No. 1, 1979, Pages 64-74 (and English version as translated in corresponding English language publication)			
	<u> </u>	ВМ	Nifantyev, et al., "Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)			
		BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> <u>Chemistry of the USSR (English Translation</u> 13:1489-1492 (1977))			
		ВО	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)			
		BP	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S24 (1993)			
		BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," <u>Bull. Inst. Chem. Acad. Sin</u> , 41: 9-16 (1994)			
		BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and <i>in Vitro</i> Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1957-1864 (1994)			
		BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)			
	Y	ВТ	Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)			

EXAMINER:			\bigcirc /	11
Examiner	Der	w/	11	[]]

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next